Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Core Insights - Perspective Therapeutics, Inc. announced that data on its [Pb]VMT-α-NET and [Pb]VMT01 programs have been accepted for presentation at the 2025 ASCO Annual Meeting, highlighting the company's ongoing commitment to advancing cancer treatments [1][2] Group 1: Company Overview - Perspective Therapeutics is a radiopharmaceutical development company focused on pioneering advanced treatments for various cancers using alpha-emitting isotopes [5] - The company employs a "theranostic" approach, combining targeted radiation therapy with imaging diagnostics to personalize treatment and optimize patient outcomes [5] Group 2: Clinical Programs - The [Pb]VMT-α-NET program targets SSTR2-positive neuroendocrine tumors and is currently in a multi-center, open-label dose escalation study [3] - The [Pb]VMT01 program is designed for MC1R-positive metastatic melanoma and is also undergoing a multi-center, open-label dose finding study [4] - Initial results from both programs have been presented at various oncology conferences, indicating ongoing research and development efforts [3][4] Group 3: Upcoming Presentations - The presentation of [Pb]VMT-α-NET will include data on dose-limiting toxicity and a one-year follow-up of participants, scheduled for May 30, 2025 [2] - The interim safety and efficacy data for [Pb]VMT01 in melanoma will be presented as a poster on June 2, 2025 [2]